摘要
Purpose: We investigated the potential value of <sup>11</sup> C-acetate (ACT) PET/CT in characterizing multiple myeloma (MM) compared with <sup>18</sup> F-FDG PET/CT. Bone marrow histological and whole-body (WB) MRI findings served as the reference standards. Methods: In this prospective study, 15 untreated MM patients (10 men and 5 women, age range 48-69 years) underwent dual-tracer <sup>11</sup> C-ACT and <sup>18</sup> F-FDG PET/CT and WB MRI for pretreatment staging, and 13 of them had repeated examinations after induction therapy. Diffuse and focal bone marrow uptake was assessed by visual and quantitative analyses, including measurement of the maximum standardized uptake value (SUV <sub>max</sub> ). Between-group differences and correlations were assessed with the Mann-Whitney U test and the Pearson test. Results: At staging, all 15 patients had diffuse myeloma involvement upon bone marrow examination with 30-90 % of plasma cell infiltrates. Diffuse infiltration was detected in all of them (100 %) using <sup>11</sup> C-ACT with a positive correlation between bone marrow uptake values and percentages of plasma cell infiltrates (r = +0.63, p = 0.01). In contrast, a diagnosis of diffuse infiltration could be established using <sup>18</sup> F-FDG in only six patients (40 %). Focal lesions were shown in 13 patients on both <sup>11</sup> C-ACT PET/CT and WB MRI, and in 10 patients on <sup>18</sup> F-FDG PET/CT. Focal lesions demonstrated <sup>11</sup> C-ACT uptake with a mean SUV <sub>max</sub> of 11.4 ± 3.3 (range 4.6-19.6, n = 59), which was significantly higher than the <sup>18</sup> F-FDG uptake (mean SUV <sub>max</sub> 6.6 ± 3.1, range 2.3-13.7, n = 29; p < 0.0001). After treatment, the diffuse bone marrow <sup>11</sup> C-ACT uptake showed a mean SUV <sub>max</sub> reduction of 66 % in patients with at least a very good partial response versus 34 % in those with at most a partial response only (p = 0.01). Conclusion: PET/CT using <sup>11</sup> C-ACT as a biomarker showed a higher detection rate for both diffuse and focal myeloma lesions at diagnosis than using <sup>18</sup> F-FDG, and may be valuable for response assessment. © 2013 Springer-Verlag Berlin Heidelberg.